Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Low Responders After Bariatric Surgery
NCT06287307Phase 4Not yet recruiting
- Sponsor
- Zuyderland
- Start
- May 2024
- Primary completion
- Feb 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by Zuyderland. Planned start May 2024; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06287307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06287307.